Vanadium - An element of atypical biological significance

Toxicology Letters

Volumn 150, Issue 2, 2004, Pages 135-143

  Mukherjee, Biswajit ^a,b   Patra, Balaram ^a   Mahapatra, Sushmita ^a   Banerjee, Pratik ^a   Tiwari, Amit ^b   Chatterjee, Malay ^a  

^a JADAVPUR UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Anti carcinogenic; Anti diabetic; Nutrition; Vanadium

Indexed keywords

AMMONIUM VANADATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P70; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VANADATE SODIUM; VANADIC ACID; VANADIUM; VANADYL DERIVATIVE; VANADYL SULFATE;

ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; BREAST ADENOCARCINOMA; CHRONIC TOXICITY; CYTOTOXICITY; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; EYE IRRITATION; FECES; GENE EXPRESSION; GENOTOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INTESTINE ABSORPTION; LD 50; LEISHMANIASIS; LIPID METABOLISM; LIVER TUMOR; METAL METABOLISM; MINERAL DEFICIENCY; MUTAGENICITY; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKELETON MALFORMATION; STOMACH ABSORPTION; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; TISSUE DISTRIBUTION; VANADATES; VANADIUM;

EID: 1842850730     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2004.01.009     Document Type: Review

References (72)

1. Alimonti A., Petrucci F., Krachler M., Bocca B., Caroll S. Reference values for chromium, nickel and vanadium in urine of youngsters form the urban area of Rome. J. Environ. Monit. 2:2000;351-354.
2. Almedeida M., Filipe S., Hunianes M., Mala M.F., Melo R., Severino N., Silva J.A., Frueesto da Silva J.J., Wever R. Vanadium haloperoxidases from brown algae of the Laminariaceae family. Phytochemistry. 57:2001;633-642.
3. Altamirano-Lozano M., Alvarez-Barrera L., Valverde M., Rojas E. Reprotoxic and genotoxic studies of vanadium pentoxide in male mice. Teratog. Carcinog. Mutagen. 16:1996;7-17.
4. Badmaev V., Prakash S., Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J. Altern. Complement. Med. 5:1999;273-291.
5. Bannasch P., Klimek F., Mayer D. Early bioenergetics changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J. Bioenerg. Biomemb. 29:1997c;303-313.
6. Bannasch, P., Zerban, H., Ahn, Y.S., Hacker, H.J., 1997b. Renal cell adenoma and carcinoma, rat. In: Jones, T.C., Popp, J.A., Mohr, U. (Eds.), Monographs on Pathology of Laboratory Animals, Urinary system, second ed., Springer-Verlag, Berlin, Heidelberg, New York, pp. 79-118.
7. Bannasch, P., Zerban, H., Hacker, H.J., 1997a. Foci of altered hepatocytes, rat. In: Jones, T.C., Popp, J.A. and Mohr, U. (Eds.), Monographs on pathology of laboratory animals, Digestive system, second ed., Springer-Verlag, Berlin, Heidelberg, New York, pp. 3-37.
8. Barceloux D.G. Vanadium. J. Toxicol. Clin. Toxicol. 37:1999;265-278.
9. 3. Biochem. Biophys. Acta. 150:2000;273-282.
10. 3 inhibit placental glutathione S-trasferase positive foci in rat liver carcinogenesis. Life Sci. 68:2000;217-231.
11. Bhanot S., McNeill J.H. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension. 24:1994;625-632.
12. Bishayee A., Chatterjee M. Inhibition of altered liver cell foci and persistent nodule growth by vanadium diethyl nitro samine-hepatocarcinogenesis in rats. Anticancer Res. 15:1995a;455-462.
13. Bishayee A., Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethyl nitrosamine and promoted by phenobarbital. Br. J. Cancer. 71:1995b;1214-1220.
14. Bishayee A., Oinam S., Basu M., Chatterjee M. Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes. Breast Cancer Res. Treat. 63:2000;133-145.
15. Bishayee A., Roy S., Chatterjee M. Characterization of selective induction and alteration of xenobiotic blotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol. Res. 111:1999;41-53.
16. Boden G., Chen X., Ruiz J., Van Rossum G.D., Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulindependent diabetes mellitus. Metabolism. 45:1996;1130-1135.
17. Bollen M., Miralpeix M., Ventura F., Toth B., Bartrons R., Stalmans W. Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase. Biochem. J. 267:1990;269-271.
18. Bosch F., Hatzoglou M., Park E.A., Hanson R.W. Vandate inhibits expression of the gene for phosphoenol carboxykinase (GTP) in rat hepatoma cells. J. Biol. Chem. 265:1990;13677-13682.
19. Cam M.C., Brownsey R.W., McNeill J.H. Mechanisms of vanadium action: insulin-mimetic and insulin-enhancing agensts? Can. J. Physiol. Pharmacol. 78:2000;829-847.
20. Cam M.C., Li W.M., McNeill J.H. Partial preservation of pancreatic beta cells by vanadium: evidence for long-term amelioration of diabetes. Metabolism. 46:1997;769-778.
21. Chakraborty A., Sevaraj S. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in Sprague-Dawley rats. Neoplasma. 47:2000;81-89.
22. Chong I.W., Lin S.R., Hwang J.J., Huang M.S., Wang T.H., Tsai M.S., Hou J.J., Paulauskis J.D. Expression and regulation of macrophage inflammatory protein-2 gene by vanadium in mouse macrophages. Inflammation. 24:2000a;127-139.
23. Chong I.W., Shi M.M., Love J.A., Christiani D.C., Paulauskis J.D. Regulation of chemokine mRNA expression in a rat model of vanadium induced pulmonary inflammation. Inflammation. 24:2000b;505-517.
24. Clarkson P.M., Rawson E.S. Nutritional supplements to increase muscle mass. Crit. Rev. Food Sci. Nutr. 39:1999;317-328.
25. Cortizo A.M., Molinuevo S., Etcheverry S.B. A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR 106 osteosarcoma cell lines. Toxicology. 147:2000;89-99.
26. Dai S., Thompson K.H., Vera E., McNeill J.H. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate. Pharmacol. Toxicol. 75:1994;265-273.
27. Ding M., Li J.J., Leonard S.S., Ye J.P., Shi X., Colburn N.H., Castranova V., Vallyathan V. Vanadate-induced activation of activator protein-1 role of reactive oxygen species. Carcinogenesis. 20:1999;663-668.
28. Djordjevic C., Wampler G.L. Anti-tumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J. Inorg. Biochem. 25:1985;51-55.
29. D'Onofrio F., Le M.Q.U., Chiasson J.-L., Srivastava A.K. Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett. 340:1994;269-275.
30. +2 channel activation and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation. J. Immunol. 164:2000;679-687.
31. Fantus I.G., Deragon G., Lai R., Tang S. Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol. Cell. Biochem. 153:1995;103-112.
32. Fawcett J.P., Farquhar S.J., Thou T., Shand B.I. Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol. Toxicol. 80:1997;202-206.
33. Goldwaser I., Qian S., Gershonov E., Fridkin M., Shechter Y. Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators. Mol. Pharmacol. 58:2000;738-746.
34. Guidotti T.L., Audette R.J., Martin C.J. Interpretation of the trace metal analysis profile for patients occupationally exposed to metals. Occup. Med. (Lond.). 47:1997;497-503.
35. Hamel F.G., Duckworth W.C. The relationship between insulin and vanadium metabolism in insulin target tissues. Mol. Cell. Biochem. 153:1995;95-102.
36. Hanauske U., Hanauske A.R., Marshall M.H., Muggia V.A. Biphasic effect of vanadium salts on in vitro tumor colony growth. Int. J. Cell. Clon. 5:1987;170-178.
37. Harding M.M., Mokdsi G. Antitumor metallocenes: structure-activity studies and interactions with biomolecules. Curr. Med. Chem. 7:2000;1289-1303.
38. Hirano S., Suzuki K.T. Exposure metabolism and toxicity for rare earths and related compounds. Environ. Health. Perspect. 104:1996;85-95.
39. Huang C., Zhang Z., Ding M., Li J., Ye J., Leonard S.S., Shen H.M., Butterworth L., Lu Y., Costa M., Rojanasakul Y., Castranova V., Vallyathan V., Shi X. Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis. J. Biol. Chem. 275:2000;32516-32522.
40. Jaspers I., Samet J.M., Erzurum S., Reed W. Vanadium-induced kappa B dependent transcription depends upon peroxide-induced activation of the p38 mitogen-activated protein kinase. Am. J. Respir. Cell. Mol. Biol. 23:2000;95-102.
41. Jaspers I., Samet J.M., Reed W. Arsenite exposure of cultured airway epithelial cells activates kappa B-dependent interleukin-8 gene expression in the absence of nuclear factor-kappa B nuclear traslocation. J. Biol. Chem. 274:1999;31025-31033.
42. Kingsmorth A.N., LaMuraglia G.M., Ross J.S., Malt R.A. Vandate supplementation and 1,2-dimethylhydrazine induced colon cancer in mice. Br. J. Cancer. 53:1986;683-686.
43. Lau J.Y., Qian K.P., Wu P.C., Davis G.L. Ribonucleotide vanadyl complexes inhibit polymerase chain reaction. Nucleic Acids. Res. 21:1993;777.
44. Li J., Elberg G., Crans D.C., Shechter Y. Evidences for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects. Biochemistry. 35:1996;8314-8328.
45. Liobet J.M., Domingo J.L. Acute toxicity of vanadium compounds in rats and mice. Toxicol. Lett. 23:1984;227-231.
46. Matte C., Marquis J.F., Blanchette J., Gros P., Faure R., Posner B.I., Olivier M. Peroxovanadium-mediated protection against murine leishmaniasis: role of the modulations of nitric oxide. Eur. J. Immunol. 30:2000;2555-2564.
47. Morinville A., Maysinger D., Shaver A. From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Trends Pharmacol. Sci. 19:1998;452-460.
48. Murthy M.S., Rao L.N., Kuo L.Y., Toney J.H., Marks T.J. Anti-tumor and toxicologic properties of the organometallic anti-cancer agent vanadocene dichloride. Inorg. Chem. Acta. 152:2000;117-124.
49. Nakai M., Watanabe H., Fujiwara C., Kakegawam H., Satoh T., Takada J., Matsushita R., Sakurai H. Mechanism of insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. Biol. Pharm. Bull. 18:1995;719-725.
50. Nriagu, J.P., 1998. Vanadium in the Environment, Part 2: Health Effects, John Wiley and sons, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto.
51. Ouellet M., Barbeau B., Tremblay M.J. p56(lck), ZAP-70, SLP-76, and calcium-regulated effectors are involved in NF-kappa B activation by bisperoxovanadium phosphotyrosyl phosphatase inhibitors in human T cells. J. Blol. Chem. 274:1999;35029-35036.
52. Pandey S.K., Theberge J.F., Bernier M., Srivastava A.K. Phosphatidylinositol 3-kinase requirement in activation of the ras/c-raf-l/MEK/ERK and p70 (s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate. Biochemistry. 38:1999;14667-14675.
53. Poucheret P., Verma S., Grynpas M.D., McNeill J.H. Vanadium and diabetes. Mol. Cell. Biochem. 188:1998;73-80.
54. Ramandham S., Heyliger C., Gresser M.J., Tracey A.S., McNeil J.H. The distribution and half life for retention of vanadium in organs of normal and diabetic rats orally fed vanadium(IV) and vanadium(V). Biol. Trace. Elem. Res. 130:1991;119-124.
55. Rehder D. Structure and function of vanadium compounds in living organisms. BioMetals. 5:1992;3-12.
56. Sabbioni E., Marafante E., Rade J., Gregotti C., Di Nucci A., Manzo L. Biliary excretion of vanadium in rats. Toxicol. Eur. Res. 3:1981;93-98.
57. Sabbioni E., Pozzi G., Pintar A., Cassella L., Garattini S. Cellular retention cytotoxicity and morphological transformation by vanadium(IV) and vanadium(V) in BALB/3T3 cell lines. Carcinogenesis. 12:1991;47-52.
58. Sakurai H., Tamura H., Okatani K. Mechanism for a new antitumor vanadium complex: hydroxyl radical dependent DNA cleavage by 1,10-phenanthroline-vanadyl complex in the presence of hydrogen peroxide. Biochem. Biophys. Res. Commun. 206:1995;113-137.
59. Saponja J.A., Vogel H.J. Metal-ion binding properties of the transferrins, a vanadium-51 NMR study. J. Inorg. Biochem. 62:1996;253-270.
60. Setyawati I.A., Thompson K.H., Yeun V.G., Sun Y., Battell M., Lyster D.M., Vo C., Ruth T.J., Zeisler S., McNeill J.H., Orvig C. Kinetic analysis and comparison of uptake, distribution, and excretion of 48 V-labeled compounds in rats. J. Appl. Physiol. 84:1998;569-575.
61. Shi X., Jiang H., Mao Y., Ye J., Saffiotti U. Vanadium(IV) mediated free radical generation and related 2′-deoxyguanosine hydroxylation and DNA damage. Toxicology. 106:1996;27-38.
62. Smith J.B. Vanadium ions stimulate DNA synthesis in Swiss mouse 3T3 and 3T6 cells. Proc. Nalt. Acad. Sci. U.S.A. 80:1983;6162-6166.
63. Stankiewicz, P.J., Tracey, A.S., 1995. Stimulation of enzyme activity by oxovanadium complexes. In: Sigel, H., Sigel, A. (Eds.) Metal Ions in Biological System, Vanadium and its Role in Life, vol. 31. Marcel Dekker, New York, Basel, Hong Kong, pp. 249-285.
64. Stemmler A.J., Burrows C.J. Guanine versus deoxyribose damage in DNA oxidation mediated by vanadium(IV) and vanadium(V) complexes. J. Biol. Inorg. Chem. 6:2001;100-106.
65. Thompson H.J., Chasteen N.D., Meeker L.D. Dietary vanadyl(IV) sulfate inhibits chemically induced mammary carcinogenesis. Carcinogenesis. 5:1986;849-851.
66. Thompson K.H., Leichter J., McNeil J.H. Studies of vanadyl sulfate as a glucose-lowering agent in STZ diabetic rats. Biochem. Biophys. Res. Commun. 97:1993;1549-1555.
67. Tracey A.S. Hydrooxamido vanadates, aqueous chemistry and function in protein tyrosine phosphatases and cell cultures. J. Inorg. Biochem. 80:2000;11-16.
68. Venugopal, B., Luckey, T.D., 1978, In: Mammals, chemical toxicity of metals and metalloids. Metal toxicity, vol 2. Plenum Press, New York.
69. Vernie L.N. Selenium in carcinogenesis. Biochem. Biophys. Acta. 783:1982;203-217.
70. Wang J., Yuen V.G., McNeill J.H. Effect of vanadium on insulin sensitivity and appetite. Metabolism. 50:2001;667-673.
71. Wilsky G.R., Goldfine A.B., Kostyniak P.J., McNeil J.H., Yang L.O., Khan H.R., Crans D.C. Effects of vanadium(IV) compounds in the treatment of diabetes: in vitro and in vivo studies with vanadyl sulfate and bis (malto lato) oxovanadium(IV). J. Inorg. Biochem. 85:2001;33-42.
72. Ye J., Ding M., Zhang X., Rojanasakul Y., Nedospasov S., Vallyathan V., Castranova V., Shi X. Induction of TNFalpha in macrophages by vanadate is dependent on activation of transcription factor N-F-kappa B and free radical reactions. Mol. Cell. Biochem. 198:1999;193-200.